Environmental Tax Reform and Corporate Earnings Management in China
Sustainability · 13.11.2026 · 18 (22) · 11572
DOI: 10.3390/su182211572 ↗Kurz gefasst
Fachartikel in der Zeitschrift Sustainability, online erschienen am 13.11.2026. Verfasst von Zixi Li und 4 weiteren Autor:innen. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Environmental taxation may alter firms’ reporting incentives during policy transitions. This study examines differential changes in accrual-based earnings management across industry-defined exposure groups following China’s 2018 environmental tax reform. Using 21,647 firm-year observations for Chinese listed companies during 2014–2021, we estimate models with firm and year fixed effects. The baseline indicates a positive shift in signed discretionary accruals under firm-clustered inference. Alternative signed-accrual measures and fixed pre-reform assignments also yield positive estimates. Additional real-activities and subgroup analyses show specification-dependent responses. Profitability variability provides auxiliary evidence concerning a performance-pressure interpretation. The findings identify a financial reporting dimension of corporate adjustment to environmental policy and motivate attention to disclosure and oversight during transitions.
Zitieren
APA
Li, Z., Liu, Y., Cai, Z., Chen, Y., & Jiang, P. (2026). Environmental Tax Reform and Corporate Earnings Management in China. Sustainability, 18(22), 11572. https://doi.org/10.3390/su182211572
Vancouver
Li Z, Liu Y, Cai Z, Chen Y, Jiang P. Environmental Tax Reform and Corporate Earnings Management in China. Sustainability. 2026;18(22):11572. doi:10.3390/su182211572
BibTeX
@article{Li2026,
author = {Li, Zixi and Liu, Yixin and Cai, Zhongyao and Chen, Yuanxiang and Jiang, Ping},
title = {Environmental Tax Reform and Corporate Earnings Management in China},
journal = {Sustainability},
year = {2026},
volume = {18},
number = {22},
pages = {11572},
doi = {10.3390/su182211572}
}
EUVIMED